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Abstract | Autologous haematopoietic stem cell transplantation (AHSCT) is a 
multistep procedure that enables destruction of the immune system and its 
reconstitution from haematopoietic stem cells. Originally developed for the treatment 
of haematological malignancies, the procedure has been adapted for the treatment of 
severe immune-mediated disorders. Results from ~20 years of experience make a 
compelling case for selective use and further trials of AHSCT in patients with highly 
active multiple sclerosis (MS). Immunological studies support the notion that AHSCT 
causes qualitative immune resetting, and have provided insight into the mechanisms 
that might underlie the powerful treatment effects that last well beyond recovery of 
immune cell numbers. Indeed, studies have demonstrated that AHSCT can entirely 
suppress MS disease activity for 4–5 years in 70–80% of patients, a rate that is 
higher than those achieved with any other therapies for MS. Treatment-related 
mortality, which was 3.6% in studies before 2005, has decreased to 0.3% in studies 
since 2005. Current evidence indicates that the patients who are most likely to 
benefit from and tolerate AHSCT are young, ambulatory and have inflammatory MS 
activity MS. Clinical trials are required to rigorously test the efficacy, safety and cost-
effectiveness of AHSCT against highly active MS drugs.
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Ablation of the immune system followed by autologous haematopoietic stem cell 
transplantation (AHSCT) for the treatment of multiple sclerosis (MS) has been 
explored for approximately two decades, since the original, pivotal report of its 
feasibility1. Studies have demonstrated that AHSCT has a high efficacy for the 
suppression of inflammatory MS activity (clinical relapses and activity detectable with 
MRI)2,3 and provided evidence that the procedure leads to neurological improvement 
in patients with relapsing–remitting MS (RRMS)4. AHSCT-related mortality, which 
was initially high and deterred referrals for the treatment (offered either in trials or 
compassionately) has decreased over the past decade. The field has been 
strengthened by mechanistic studies that have demonstrated that so-called immune 
resetting underlies the anti-inflammatory effects of the treatment5-8 and by the 
publication of clinical studies in the past 2 years that have demonstrated 
considerable efficacy and acceptable safety9-14. Furthermore, mass media has 
repeatedly featured AHSCT, raising public interest but also inducing some unrealistic 
expectations among patients with MS and their families, as well as causing confusion 
among clinicians who are inexperienced in this treatment.  
 
In this Review, we aim to provide a clear and informative description of the treatment 
procedure for AHSCT, and an overview of current knowledge and outstanding 
questions about the mechanism of action of the treatment. We then present an up-to-
date critical analysis of the published evidence on the efficacy and risks of AHSCT, 
and give our expert opinion on optimal patient selection and treatment methodology. 
We also discuss further research required to optimally define the safety, efficacy and 
cost-saving opportunities of AHSCT compared with currently approved therapies for 
MS. 
 
[H1] Unmet needs in MS therapy 
MS affects over 2.3 million people worldwide and is the most common nontraumatic 
cause of disability in young adults. Besides the incalculable effect on individuals’ 
quality of life, the annual fiscal cost of MS in Europe has been estimated at €14.6 
billion15. Nevertheless, the development of treatments for MS has been a success 
story since the 1990s, when the first therapeutics were licensed for the treatment of 
RRMS. The introduction of the number of brain lesions detected with MRI as an 
outcome in phase II trials in RRMS has accelerated the licensing of new therapies 
owing to its excellent association with relapses in trials of up to 3 years16. At least ten 
disease-modifying treatments are now available for RRMS. Treatment development 
in RRMS has been characterized by phase II trials in which the MRI markers of 
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disease activity have been targeted, and phase III trials of up to 3 years in which 
clinical relapses and/or evolution of disability evolution have been targeted. However, 
trials have not demonstrated consistent effects on disability progression which has 
the greatest impact on the lives of people with MS. In addition, little evidence is 
available to inform the optimal choice of disease-modifying treatment for individual 
patients or when to stop and change therapy. Opinions and practices are split 
between escalation and induction approaches. In escalation therapy, the safest 
agent — which is not necessarily the most effective — is tried first and more active 
agents, which usually entail higher risks, are only used if disease activity persists or 
breaks through. Induction therapy aims to stop or cure the condition before it 
produces major adverse effects, although might be associated with higher risks. 
Alemtuzumab is the licensed therapy that most closely meets the definition of an 
induction therapy, but is used more frequently after failure of first-line agents.  
 
Besides uncertainty about optimal treatment strategies for RRMS, clear unmet needs 
exist for effective disease-modifying treatment in certain sub-groups of MS: 
aggressive MS, treatment-refractory MS and progressive MS (Box A). These non-
mutually exclusive groups can occur at different stages in the natural history of MS, 
but are all thought to be associated with a worse prognosis than mild to moderate 
RRMS that responds adequately to disease-modifying treatment. 
 
AHSCT is a one-off treatment designed to eradicate or induce long-term suppression 
of MS, and could meet the definition of an ideal induction therapy that could be used 
to treat even the most aggressive disease. To date, however, AHSCT has 
predominantly been employed as a rescue therapy after an escalation sequence in 
which more than one line of treatment has failed. 
 
[H1] Fundamentals of AHSCT 
 
Haematopoietic stem cell transplantation is a well-established multistep procedure 
designed to replace the blood and lymphoid systems of a patient with a new one 
derived from haematopoietic stem cells (HSCs). HSCs can be collected from either a 
healthy donor (allogeneic transplantation) or from the patient (autologous 
transplantation). The procedure has been used extensively in the past 50 years for 
the treatment of aggressive haematological malignancies, such as leukaemia and 
lymphoma17. Allogeneic transplantation is most frequently used for malignant 
indications, but carries the risk of graft-versus-host disease (GVHD), which increases 
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transplant-related mortality. The risk is partially offset by a lower incidence of 
leukemia relapse than that observed with autologous transplantation, an advantage 
that is attributed to a graft-versus-leukaemia effect. The prevention of relapse by 
means of graft-versus-host effects has also been reported in autoimmune disease 
(graft-versus-autoimmunity)18, but the risk of transplant-related mortality from 
allogeneic transplantation is generally considered unacceptable in non-neoplastic 
diseases. Consequently, only autologous transplantation is being developed for the 
treatment of MS19. 
 
[H2] The procedure 
The AHSCT procedure comprises four main steps: HSC mobilization, HSC 
harvesting, ablative conditioning and HSC re-infusion or ‘transplantation’ (Figure 1). 
Initially, HSCs were obtained by aspiration of the bone marrow, but are increasingly 
harvested from peripheral blood after so-called mobilization. HSC mobilization (step 
1) involves administration of granulocyte colony-stimulating factor (G-CSF), either 
alone or with cytotoxic chemotherapy, such as cyclophosphamide. HSCs that have 
been mobilized are then harvested from peripheral blood by leukoapheresis (step 2). 
The HSCs are cryopreserved and stored frozen until the patient is ready for 
transplantation. Before transplantation, ablation of the haemato-lymphopoietic 
system is achieved with high-dose chemotherapy (or chemo-radiotherapy when 
associated with total body irradiation, which is no longer used for MS but is for other 
indications; this stage is known as the preparative or conditioning regimen (step 3). 
Immediately after completion of the conditioning regimen, patients develop 
pancytopaenia and a transient bone marrow aplasia, and intravenous infusion of the 
stored HSCs (transplantation, step 4) is required to enable marrow repopulation, 
recovery of haematopoiesis, and immune reconstitution. 
The duration of steps 1 and 2 is 5–15 days, depending on the protocols employed, 
and can be performed in day care or with a short hospital admission. Steps 3 and 4 
require hospital inpatient admission to enable close monitoring and supportive care. 
Ablative conditioning therapy generally starts at least 2–4 weeks after completion of 
HSC harvesting, but should not be delayed if it is safe to proceed. Patients are 
usually admitted for 3 weeks20. 
 
[H2] Mechanisms of action 
 
[H3] Rationale 
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Immune-related genetics are important in the aetiology of MS: the HLA-DR15 
haplotype is a major risk factor, and >100 common genetic variants — which are 
enriched for immunologically relevant genes — are associated with the disease21. 
However, genetics explain only a small amount of the risk of developing MS. Several 
environmental risk factors, including Epstein–Barr virus infection22, low vitamin D3 
levels 23, smoking24 and obesity25, have been identified. Events that can initiate MS 
have not yet been identified, but current evidence suggests that the process involves 
aberrant activation or failed regulation of proinflammatory T cells, including CD4+ TH 
cells that secrete IFN-γ (TH1 cells), IFN-γ and IL-17 (TH1* cells), and IL-17 alone 
(TH17 cells). In pattern II MS pathology, TH2 cells26 have been identified, together 
with CD8+ T cytotoxic cells, B cells and macrophages. Detailed information about the 
immunopathological process is available elsewhere27,28. On this basis, the application 
of AHSCT to MS is intended to eliminate the aberrant adaptive immune system via 
the conditioning regimen and subsequently rebuild the immune system in the hope 
that immune tolerance will be re-established. 
 
  
[H3] Immune resetting 
Studies from the past decade have shown that rebuilding of the immune system is 
indeed possible. Immediately after the AHSCT procedure, a broad spectrum of 
lymphoid and myeloid cells is either completely eliminated or depleted (depending on 
the intensity of the conditioning regimen) — these cells include adaptive immune 
cells (T cells and B cells) and innate immune cells (natural killer cells, dendritic cells, 
monocytes and granulocytes). Subsequently a ‘new’ immune system gradually 
develops from the CD34+ haematopoietic stem cells. Natural killer cells, CD8+ T cells 
and B cells are repopulated in the first few weeks to 6 months29-33, whereas 
reconstitution of the CD4+ repertoire takes up to 2 years5. Important questions that 
have been addressed about this process include how immune cells redevelop in 
adults with an inactive remnant thymus, and whether the immune repertoire after 
AHSCT is indeed new, rather than the result of expansion of and possible acquisition 
of new functional phenotypes by cells that survive the conditioning or are present in 
the graft. Studies that have addressed these questions, described below, have 
allowed a working model to be constructed for the mechanisms of AHCST in MS 
(Figure 2). 
  
[H3] T cells 
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On the basis of our understanding of MS pathogenesis, outlined above, the effect of 
AHSCT on T cells has been the main focus of research into the mechanisms. The 
first notable observation about T-cell repertoire reconstitution was that naive T cells 
re-emerged over time after AHSCT and showed signs that they had developed in a 
re-activated thymus5. In the first notable study, analysis of the cellular marker CD31 
and so-called T cell receptor excision circles, which mark recent thymic emigrants, 
showed that T cells generated after AHSCT had undergone positive selection and 
matured in the thymus5. Further evidence for true T cell renewal was obtained from 
DNA sequencing to enable comparison of the complementarity determining region 3 
(CDR3) of T cell receptors (TCRs): comparison of CDR3 sequences from CD4+ and 
CD8+ T cells before and after AHSCT demonstrated not only that the T cell repertoire 
was substantially more diverse after AHSCT but also that almost all CD4+ T cells that 
were present before AHSCT had gone, and new clones had developed5. A deep 
sequencing study that included millions of TCRs confirmed that repertoire renewal is 
almost complete for CD4+ T cells, but is less so for CD8+ T cells, in which clonal 
persistence was seen8. One phenotypic study has revealed that levels of presumably 
pathogenic CD4+ TH17 cells were reduced after AHSCT, whereas the frequencies of 
TH1 and TH2 cells, which have the potential to induce inflammation and antibody 
production, respectively, in MS, did not change7. Besides transient increases of 
CD4+CD25highFoxP3+ Treg cells and of CD56bright natural killer cells (cells with reported 
immune regulatory activity27), the post-transplant T-cell repertoire was characterized 
by expansion of CD8+CD57+ T cells with the potential to kill autologous CD4+ T cells 
and therefore curtail TH activities6. In the same study, mucosal associated invariant T 
(MAIT) cells (characterized by expression of CD8, high expression of CD161 and 
secretion of IL–17 and IFN–γ) were observed in active MS lesions in post-mortem 
brain tissue and in the peripheral blood of patients before therapy, but this candidate 
inflammatory cell population was significantly more depleted after AHSCT than after 
conventional treatments.  
Limited data are available about the antigen specificity of T cells after AHSCT. 
Myelin-specific T cells are known to develop after AHSCT7,34, but such T cells are 
part of the physiological immune repertoire35 and more detailed studies of their 
antigen avidity, functional phenotype and migratory potential are needed to discern 
whether potentially pathogenic cells redevelop. Evidence from AHSCT for juvenile 
idiopathic arthritis and dermatomyositis indicates that Treg cells have limited TCR 
diversity before AHSCT, but are present in greater numbers and more diverse after 
AHSCT36. Expansion of CD4+CD25highFoxP3+ Treg cells and increased expression of 
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the regulatory markers CTLA-4 and GITR on CD4+CD25high cells after AHSCT37 
suggest improved control of T cell activation. 
[H3] B cells 
The effects of AHSCT on B cells and the humoral immune response have been 
studied less than those on T cells, particularly in MS. Ablative conditioning eliminates 
B cells at almost all stages of differentiation, except long-lived plasma cells. During 
development of the post-AHSCT B cell repertoire, naive and memory B cell subtypes 
are reconstituted although data on their functional phenotypes are lacking. In 
systemic lupus erythematosus (SLE), AHSCT reduces or eliminates anti-DNA 
antibodies, normalizes B cell homeostasis and induces recovery of B cell numbers38. 
These data are consistent with the demonstrated development of a diverse and 
adult-like immunoglobulin repertoire beyond 4 months after AHSCT39. Whether these 
findings are the same in MS is currently unclear, but the persistence of oligoclonal 
bands in one study suggests that immunoglobulin-producing cells in the CNS 
compartment are insufficiently ablated 40. 
[H3] Gene expression 
Gene expression and regulation by microRNAs (miRNAs) in the newly emerging 
immune repertoire have been studied to gain insight into the mechanisms of immune 
reconstitution. Comparison of gene expression profiles of CD4+ and CD8+ T cells 
from patients with MS before and after AHSCT has demonstrated normalization of 
the profiles: in CD8+ cells, the profiles were more similar to those of cells from 
unrelated healthy controls than to those of patients’ pre-treatment or early post-
treatment cells41. In another study, expression of the miRNAs miR-16, miR-155 and 
miR-142-3P, which regulate T cell activation and are aberrantly expressed in MS, 
normalized after AHSCT; expression of their putative target genes — FOXP3, 
FOXO1, PDCD1 and IRF2BP2 — increased, as expected37. These data agree with 
previous findings that the gene and miRNA expression signatures of CD34+ HSCs of 
patients with MS is not different from healthy controls, indicating that these cells do 
not have a preprogrammed proinflammatory state42. 
[H1] Clinical use of AHSCT 
[H2] Efficacy 
Besides isolated reports of AHSCT being used for early treatment of highly 
aggressive relapsing inflammatory forms of MS43,44, the initial clinical studies of 
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AHSCT in MS were conducted almost exclusively in patients with high levels of 
disability and progressive disease45-48. Accordingly, in a retrospective long-term 
analysis published in 201260, 78% of 281 patients with MS who underwent AHSCT 
between 1996 and 2005 had progressive MS (66% had secondary progressive MS) 
and the median EDSS score before the procedure was 6.5. In this study, a younger 
age, RRMS and fewer prior disease-modifying treatments were associated with 
better neurological outcomes. Consequently, subsequent studies of AHSCT have 
predominantly included patients with RRMS and an aggressive disease course9-11,49. 
Almost all studies of AHSCT in MS have been observational cohort studies in which 
the efficacy was evaluated by comparing disease activity before and after 
transplantation. Although this approach generates uncontrolled evidence, it is 
justified in studies of patients who have an overwhelmingly active or rapidly 
progressive course that has not responded to appropriate disease-modifying therapy, 
as randomized controlled studies with these patients would be unethical. 
Suppression or clear stabilization of such aggressive disease activity after AHSCT 
can reasonably be regarded as a consequence of the procedure. 
One comparative phase II randomized clinical trial of AHSCT has been published — 
the ASTIMS trial12 — in which the effect of the treatment was compared with that of 
mitoxantrone in patients with aggressive RRMS or secondary progressive MS. The 
number of participants was low (n = 21), some data were missing and the 
methodology had other limitations as a result, in part, of the purely academic 
development of the study and the limited financial support; nevertheless, the number 
of new T2 lesions that occurred over 4 years (the primary endpoint of the study) was 
79% lower among patients who underwent AHSCT than among those who received 
mitoxantrone (P <0.001). The proportion of patients in the ASTIMS trial whose 
disability progressed after AHSCT was 33% at 2 years and 57% at 4 years, but most 
participants (67%) had secondary progressive disease at baseline. Many participants 
of other studies that have involved patients with progressive disease45,48 have also 
continued to lose neurological function, which has been interpreted as the result of 
unaffected neurodegenerative processes such as axonal injury and neuronal loss. In 
the HALT-MS study, in which only patients with RRMS were enrolled, the proportion 
of patients with disability progression after AHSCT was <10% at 2 years and 5 years9. 
Further experience of AHSCT strengthened the evidence that the therapy is most 
successful if performed in the earlier inflammatory stages of MS9,11,14, when profound 
effects are seen on MRI measures2 and relapse activity10. A study published in 2016 
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demonstrates the complete suppression of inflammatory activity that can be achieved 
with AHSCT13. For the 24 patients enrolled in this study, the mean number of 
relapses between diagnosis and AHSCT was 1.2 per year, and the mean number of 
Gadolinium-enhancing lesions seen on the baseline MRI scan (taken in the months 
preceding the start of the procedure) was 3.9. After AHSCT, no clinical relapses 
occurred in any of the 23 surviving patients during up to 13 years of follow-up, and 
none of 327 post-transplantation MRI scans showed Gadolinium-enhancing lesions.  
In the absence of direct comparisons between the efficacy of AHSCT and that of 
approved disease-modifying therapies, some insight can be gained by considering — 
with caution — the degree of control over disease activity that has been achieved in 
clinical trials of AHSCT and of treatments that have been licensed on the basis of 
their efficacy in trials. The level of control is indicated by the proportion of patients 
who achieve no evidence of disease activity (NEDA), a composite endpoint (no 
relapses, no disability progression and no MRI activity) that is often reported at 
2 years in contemporary trials and has been proposed as a treatment goal in patients 
with RRMS50. Five trials of AHSCT published since 2010 have reported the 
proportion of patients with RRMS for whom NEDA was achieved at 2 years after 
transplantation9-11,13,14,47, and these reports have enabled comparisons with trials of 
other disease-modifying therapies that are either approved or close to approval51. A 
cross-sectional analysis reveals that the proportion for whom NEDA was achieved at 
2 years was 7–16% among those who received placebo, 13–27% among patients 
who received IFNβ-1a, and 22–48% among patients who received other active drugs; 
among patients who underwent AHSCT, the proportion was considerably higher, at 
70–92% (Figure 3). Moreover, in trials of drugs, NEDA status was more frequently 
lost owing to new inflammatory activity, whereas disease activity after transplantation 
is mainly accounted for by disability progression, especially in studies that included 
patients with progressive disease12,45,48. 
As noted51, these comparisons must be made with caution because the patient 
populations and follow-up schedules differed between trials. Nevertheless, the 
difference in the achievement of NEDA with AHSCT and drug therapies cannot be 
explained by differences in the populations alone, particularly because participants of 
AHSCT trials had more aggressive disease than those of all the other clinical trials52. 
This severity of disease is illustrated by the characteristics of patients included in 
AHSCT studies published in the last 2 years (Table 2) For example, in comparison 
with the CARE MS-II trial53 — the only trial of a currently approved therapeutic that 
required one prior treatment failure for patient eligibility and consequently included a 
similar population to those in studies of AHSCT —the median EDSS score is 3.5–6 in 
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AHSCT trials, versus 2.5 in the CARE MS-II trial. Similarly, the median number of 
previous treatments was two or three versus one, and the disease duration was 5–
10.5 years versus 4.5 years, all factors that would predict a lower rate of NEDA the 
AHSCT trials than in the CARE MS-II trial. The mean age, however, was comparable: 
28–38 years versus 35 years. 
 
Some evidence suggests that AHSCT can not only reduce disease activity, but also 
improve neurological function4,9-14,54. In one large single-centre case series (n = 145), 
disability scores had improved at 2 years after AHSCT in one-third of patients11, 
predominantly those with RRMS and mild to moderate disability. Work by the same 
researchers showed that AHSCT failed to improve neurological function and stop 
worsening in patients with high levels of established disability as a result of 
progressive MS30. This dichotomy is demonstrated on a larger scale by a 
retrospective long-term analysis that demonstrated significant improvements in 
neurological function during the first year after AHSCT in patients with RRMS but not 
those with progressive MS (median EDSS score change 1 year after transplantation, 
–0.76 versus –0.14, P <0.001)60.  
 
[H2] Safety and tolerability 
The risks and adverse effects of AHSCT are influenced by the intensity of the 
procedure, and the intensity of the conditioning regimen has a dominant role. The 
clinical condition of the patient, their age and the presence of comorbidities are also 
important. 
 
[H3] Intensity of AHSCT 
The overall intensity of AHSCT can vary widely, and is determined by four main 
variables: whether chemotherapy is administered for HSC mobilization; whether the 
haematopoietic graft is manipulated to enrich HSCs (CD34+ selection) and remove 
immune cells (ex vivo T-cell depletion); the intensity of the conditioning regimen, 
which depends on the type and dose of the agents used; and whether in vivo 
lymphodepleting serotherapy, such as antilymphocyte or antithymocyte globulin 
(ATG), is administered. Working definitions that evolved around haematopoietic 
transplantation for the treatment of cancer are used to distinguish between 
myeloablative conditioning, reduced-intensity conditioning and nonmyeloablative 
conditioning, based on the duration of cytopaenia and on the requirement for HSC 
support55. These designations have also been used by some clinicians to qualify 
different conditioning regimens for autoimmune disease, and have been popular in 
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discussions on social media amongst people with MS. In transplantation for 
autoimmune disease, conditioning regimens are classified and defined in the 
European Society for Blood and Marrow Transplantation (EBMT) guidelines56 as 
high-intensity, intermediate-intensity and low-intensity. In a recent meta-analysis of 
AHSCT for MS, the reported conditioning regimens were classified according to the 
EBMT guidelines57. High-intensity regimens, which usually include the use of high-
dose busulfan or total body irradiation combined with cyclophosphamide and in vivo 
and ex vivo T cell depletion, were more frequently used in earlier trials30,31,45,48,58, 
partly as a result of sporadic reports of AHSCT for autoimmune disease in which less 
intense protocols were used and were followed by a high incidence of relapses59. 
Neither a retrospective registry study60 nor a literature meta-analysis61, however, 
documented any advantages of high-intensity regimens over low-intensity regimens 
in terms of progression-free survival, at least in secondary progressive MS. In 
addition, life-threatening infections were reported in studies in which high-intensity 
conditioning regimens were used48,62. Partly on the basis of these concerns, low-
intensity regimens that involve administration of cyclophosphamide and ATG — also 
called nonmyeloablative regimens55 — were introduced, enabling toxicity to be 
reduced, which increased confidence in offering AHSCT earlier in the disease course, 
before the accumulation of irreversible disability in RRMS4,11. 
An intermediate-intensity conditioning regimen called BEAM, which involves a 
combination of the chemotherapeutics bis-chloroethylnitrosourea (BCNU), etoposide, 
cytosine arabinoside (ARA-C), and melphalan, has been the most frequently used 
protocol in Europe (Table 1), and has been used in American9,14,47 and Asian63 trials. 
Other intermediate-intensity, BEAM-modified regimens have also been used64,65. The 
different protocols that have been used in the treatment of MS are expected to 
produce different lymphoablative and myeloablative effects (Figure 5). Differences 
between the populations treated with different regimens mean that a reliable 
comparison of the risk–efficacy ratios between low-intensity and intermediate-
intensity regimens cannot be made.  
 
[H3] Adverse effects 
AHSCT primarily targets the immune system, and immune suppression is, therefore, 
a necessary and expected (on-target) effect of the procedure. In an analysis of 169 
patients, 79% of the early non-neurological adverse effects of AHSCT were 
secondary to the immunosuppression, and included neutropaenic fever, sepsis, 
urinary infections and viral reactivations60. 
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AHSCT can also have several off-target adverse effects. Neurological toxicity was 
reported in 26 of 149 (17%) evaluable patients in one study, and occurred within 
60 days of transplantation60. Transient alopaecia and amenorrhoea are common 
adverse effects. A small study of patients who underwent low-intensity or 
intermediate-intensity regimens demonstrated recovery of the menstrual cycle in all 
patients who were aged ≤32 years, but recovery of menstruation after treatment was 
reported up to age 41 years66. Permanent infertility is a risk, but in a retrospective 
study of 324 women who underwent HSC transplantation for autoimmune disease, 
15 pregnancies were reported, and no congenital, developmental or other disease 
was reported in the children67. Patients with MS who undergo AHSCT can 
experience disease-specific adverse effects, such as frequent urinary tract infection, 
the Uhtoff phenomenon, limb spasticity and reduced mobility, all of which can 
increase the risk of complications and require expert management68.  
Late effects, which are considered to be adverse events that arise months or years 
after completion of the procedure but might be related to it, are less common, but 
include secondary autoimmune disease, mostly thyroiditis. In two EBMT Registry 
analyses published in 2006 and 2011, the incidence of secondary autoimmune 
disease was 3.6% and 6.4%60,69. A similar incidence was reported in a study 
published in 2017 that included patients from the EBMT and the Center for 
International Blood & Marrow Transplant Research (CIBMTR) databases: new 
autoimmune disease occurred in 14 of 281 patients (5%) over a median follow-up of 
6.6 years after AHSCT that followed failure of standard immunomodulatory and 
immunosuppressive therapies (two or more previous therapies in ~70% of patients)54. 
In the same study, other late adverse events included malignancies in nine patients 
(3.2%)54. Multiple factors contribute to an individual’s risk of developing cancer, and 
the ability to estimate the additional risk as a result of AHSCT remains elusive. 
Further detail about the complications of AHSCT for the treatment of autoimmune 
disease is available elsewhere70. 
 
[H3] Treatment-related mortality 
Mortality is the main concern that has limited the development and use of AHSCT. In 
the EBMT Registry, the overall treatment-related mortality among patients with MS 
who received AHSCT is 2.0% of 829 evaluable patients (as of May 2017, with 
incomplete data for 2016). This number still incorporates high treatment-related 
mortality of 7.3% from the earliest use of the treatment during 1995–2000; marked 
decreases have been reported since, with treatment-related mortality of 1.3% during 
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2001–2007 71, further decreasing to 0.7% (4 of 565) during 2008–2016 and down to 
0.2% (1 of 439) in the past five calendar years (Figure 4). 
Similarly, a meta-analysis of 15 published studies (which included non EBMT-
registered cases) revealed treatment-related mortality of 0.3% among the 349 
patients included in seven studies in which the estimated year of transplantation was 
after 2005, a marked reduction from 3.6% among the 415 patients treated in the 
older studies57. The same meta-analysis identified an inverse relationship between 
treatment-related mortality and the proportion of patients with RRMS (rather than 
progressive MS)57. A retrospective long-term analysis of 281 patients with MS who 
underwent AHSCT during 1996–2005 produced similar findings: treatment-related 
mortality was 2.8%60, and a higher EDSS score was significantly associated with a 
higher risk of death from any cause (treatment-related and not treatment-related), 
and progressive MS and high-intensity conditioning regimens were over-represented. 
In combination, these findings indicate that improved patient selection — treatment of 
patients with RRMS and low EDSS scores — and decreased use of high-intensity 
conditioning regimens underlie the reduction in treatment-related mortality. Improved 
supportive care might also be an important factor. 
 
 
[H1] Optimization and recommendations 
[H2] Patient selection 
The opportunity for a patient to benefit from AHSCT depends mainly on their clinical 
status, in line with the hypothesis that a clear therapeutic window exists during the 
course of MS72. Given the risk and adverse effects of AHSCT, the treatment cannot 
currently be recommended for the general population of patients with MS. 
Nevertheless, AHSCT has been designated as a clinical option in the EBMT 
guidelines for the treatment of patients with aggressive MS that is unresponsive to 
conventional and approved therapies56. A critical point for patients and clinicians to 
understand, however, is that AHSCT is not a neuroregenerative treatment or a 
treatment that should be used as a last resort after failure of all available treatments. 
Rather, the optimal timing is right after failure of licensed treatment, when the 
aggressive clinical course of the disease is clear but the patient remains minimally 
compromised. The current evidence enables us to refine the profile of the ideal 
candidate for AHSCT on the basis of several important factors: relapses and the 
phase of the disease, MRI activity, age and disease duration, neurological disability, 
comorbidities, cognitive impairment and response to prior treatments (Box 1). 
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[H3] Relapses and phase of disease 
Although initial studies of AHSCT in MS predominantly included patients with 
progressive disease, a profound effect on relapses was soon documented in patients 
with RRMS32 and confirmed to varying degrees in all subsequent studies; one recent 
study demonstrated total long-term suppression of relapses13. A large body of 
evidence, therefore, supports the general consensus that the patient who would 
benefit most from AHSCT is still in the relapsing–remitting phase of the disease with 
inflammatory clinical activity (that is, relapses that can be highly effectively 
suppressed by the treatment). 
Some studies have indicated favorable outcomes of AHSCT in progressive forms of 
MS63-65,73. Following the 2013 revision of the various clinical courses of MS74, the fact 
that some patients with progressive MS experience clinical (relapses) and/or exhibit 
inflammatory activity on MRI (Gadolinium–enhancing lesions or new or enlarging T2-
positive lesions) is more widely recognized. In these patients, the inflammatory 
activity might be effectively targeted with AHSCT, as it has been with the 
immunosuppressants rituximab75 and ocrelizumab76. However, rigorous evidence 
that AHSCT improves outcomes in patients with progressive MS, even with 
inflammatory activity, is lacking. 
 
[H3] MRI markers of activity 
Gadolinium-enhancing lesions and new or enlarging T2 lesions are well-established 
indices of inflammatory MS activity. It has been clear since 2001 that AHSCT can 
completely suppress inflammatory lesion activity detectable with Gadolinium-
enhancing MRI for at least 36 months2. This abrogation of MRI activity has been 
replicated over a follow-up period of 6–7 years13. Nevertheless, a complete absence 
of MRI activity after transplantation has not been observed in every study. In one 
study in which a cyclophosphamide-based low–intensity conditioning regimen was 
used, reoccurrence of MRI inflammatory activity was frequently seen 6–12 months 
after AHSCT49. Among patients who were treated with intermediate-intensity regimes, 
such as BEAM, in several studies, 8–10% of them exhibited new or active lesions on 
MRI scans at 2–5 years after treatment9,10,14,73. 
Progression-free survival was significantly better in patients with MRI lesion activity 
at baseline than in those without in two reports10,73. The evidence from these studies, 
together with the need to demonstrate active inflammation to advocate use of a 
treatment strategy that targets inflammation, justify recent MRI inflammatory activity 
as a key requirement in patient selection for AHSCT. 
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[H3] Age and duration of disease 
In one large case series, patients aged <40 years who underwent AHSCT within 
5 years of disease onset had better progression-free survival than older patients with 
longstanding disease60. The onset of progressive disease is age-dependent, and 
usually occurs at age 40–50 years; the frequency of relapses decreases with 
increasing age77,78. In a long-term analysis, age was identified (together with 
progressive MS and number of prior immune-modifying therapies) as an independent 
factor associated with neurological progression-free survival60. The duration of 
clinical disease strongly correlates with age, so a shorter disease duration is 
expected to be associated with a higher probability of active inflammatory disease. 
Therefore, although older age alone does not negatively affect overall survival after 
AHSCT for lymphoma79, in the treatment of MS, the evidence provides the strongest 
rationale for AHSCT in young patients (aged <45 years) with a short disease duration 
(<10 years). 
 
[H3] Neurological disability 
In studies of AHSCT conducted before 2005, the baseline disability of patients was 
usually high: one study of long-term outcomes60 showed that the median EDSS 
score was 6.5. In this study, a higher EDSS score was significantly associated with 
poorer overall survival (HR 2.03 per EDSS point). Similarly, in a meta-analysis, a 
baseline EDSS score >6 was significantly associated with a higher treatment-related 
mortality (P = 0.013)57. These associations can be explained by a high incidence of 
comorbidities (such as urinary tract infections and chronic lung disease) and their 
attendant complications in non-ambulatory patients, 80 as well as a higher risk of 
death from progression of MS. Partly on the basis that higher EDSS scores are 
frequently associated with progressive MS than with RRMS, recent AHSCT studies 
have excluded patients with severe disability by, for example, limiting baseline EDSS 
scores to 5.59,11,14. 
In rare cases of extremely aggressive MS that causes a high degree of disability in a 
matter of weeks, AHSCT can be considered as a potentially lifesaving treatment and 
has been used successfully in this context43,44,81,82. Besides these situations, however, 
patients with an EDSS score <6 (ambulatory without aid) are the most appropriate 
candidates for AHSCT and, on the basis of published evidence60,57 and our clinical 
experience, we suggest that patients with established EDSS scores ≥7 are at high 
risk of complications and treatment failure, so are not appropriate candidates for 
AHSCT. 
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[H3] Previous response to MS therapies 
In the vast majority of cases, AHSCT has been offered as part of a clinical study or 
as compassionate therapy after failure of one or more disease-modifying therapies. 
Given the risks and adverse effects, treatment with AHSCT outside clinical trials 
seems reasonable and ethical only after failure of approved therapy. In line with 
contemporary views on the management of RRMS83,84, we suggest that failure of one 
licensed disease-modifying drug of high efficacy (defined as Category 285: currently 
alemtuzumab or natalizumab, but likely to include rituximab and ocrelizumab once 
approved — ocrelizumab is approved in the USA, but not yet in Europe) owing to a 
demonstrated lack of efficacy is sufficient to consider offering AHSCT to otherwise 
clinically appropriate patients with aggressive RRMS.  
For patients with average active MS (distinct from aggressive), the current prevailing 
opinion is to initiate treatment with a first-line therapy, followed by escalation to 
natalizumab, fingolimod or alemtuzumab in those who fail to respond83. In our 
opinion, escalation through two lines of therapy before considering AHSCT is 
acceptable but not required: patients who experience persistence of their disease or 
breakthrough of substantial clinical and MRI inflammatory activity during induction 
treatment with a high-efficacy monoclonal antibody (as defined above) administered 
as a first-line therapy could be considered as candidates for AHSCT, as well as for 
alternative approved high-efficacy treatment options. More than two prior 
immunotherapies, however, is associated with poorer progression-free survival after 
AHSCT 60, highlighting the limited window of opportunity for effective MS treatment, 
and that treatment escalation over several years precludes the chances of success 
with any treatment that is given too late. With >10 currently approved drugs for MS, 
the risk of missing this therapeutic window is of particular concern. 
 
[H3] Comorbidities and cognitive impairment 
Systemic and organ-specific comorbidities affect survival after AHSCT79. 
Substantial cardiac, renal, pulmonary or hepatic dysfunction, active infections, or 
other conditions that could increase the risk of severe complications and mortality, 
are contraindications for AHSCT68. The pre-transplantation workup must always 
include screening and assessment for such conditions, as detailed elsewhere56. 
Furthermore, adequate cognitive capacity is required to fully understand the possible 
adverse effects and risks of AHSCT, and to comply with treatments and 
recommendations, which are important elements in the safety of the procedure. 
 
[H2] AHSCT methodology 
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Increasing clinical experience with AHSCT is enabling refinement of the methodology 
for the procedure and development of a recommended protocol (Box 2). 
 
[H3] HSC mobilisation 
For HSC mobilization, use of high-dose cyclophosphamide with G-CSF is preferable 
to use of G-CSF alone for several reasons: the HSC yield is better; the induction 
treatment effect is potentiated by sequential immunosuppression during mobilization 
and conditioning; a lack of disease exacerbations, which have been reported with 
mobilization obtained by G-CSF alone; the number of mature immune cells in the 
graft is lower, and recovery of T cell clones from the autologous graft is poor, which 
reduces the potential for carryover of disease-mediating T cells with the transplant86. 
We support the mobilization regimen recommended by the EBMT56: 
cyclophosphamide at 2–4 g/m2 of body surface area with mesna and cautious 
hyperhydration for bladder protection, followed by 5–10 μg/kg G-CSF daily until the 
completion of HSC collection. 
 
[H3] Conditioning regimen 
The optimal intensity of the conditioning regimen remains an open question, given 
the lack of published comparative data. High-intensity regimens are burdened by a 
high toxicity profile, as indicated by previous analyses48,60, although these findings 
have not been confirmed in a larger study87. The regimen that includes high-dose 
busulfan, described in 200968 and uniquely used for treatment of MS in the study 
reported in 201613, completely suppressed MS inflammatory activity, but caused 
severe liver toxicity in two patients, which resulted in the death of one. Low-intensity 
regimens, such as those based on cyclophosphamide, are safer and require less 
supportive care; however, some data indicate that these regimens are associated 
with a higher incidence of disease reactivation4,47. The conditioning regimens with the 
strongest traction within each intensity category are cyclophosphamide and ATG (low 
intensity), BEAM and ATG (intermediate intensity) and cyclophosphamide, busulfan 
and ATG (high intensity). In the absence of evidence from randomized comparisons, 
we endorse the preferential use of BEAM and ATG — the scheme that is specifically 
recommended for the treatment of MS in the EBMT guidelines56 — by virtue of its 
extensive track record that indicates good safety and high efficacy14,73, and of the 
opportunity it provides for comparisons across data sets. 
 
[H3] Autologous HSC enrichment and dose 
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The advantage of graft purification, with CD34 selection for example, is unclear. A 
theoretical advantage is a lower risk of re-introducing mature leukocytes that might 
include pathogenic cells. However, the only randomized study in which CD34-
selected and unselected HSC grafts have been compared — conducted in patients 
with rheumatoid arthritis — showed no difference in outcomes88. Similarly, a 
retrospective analysis of AHSCT for systemic sclerosis failed to demonstrate any 
benefit of CD34 selection on patient outcomes89. Evidence in MS is limited to a small 
study of patients with progressive MS, but this work also demonstrated no obvious 
advantage of CD34 selection90. These consistently negative findings have weakened 
support for the use of CD34 selection56, especially when HSC mobilization is carried 
out with the use of high-dose cyclophosphamide with G-CSF rather than with G-CSF 
alone.  
Irrespective of graft manipulation, we support the EBMT recommendation for 
transplantation that a minimum dose of 2 × 106 CD34+ cells/kg should be reinfused56. 
However, evidence is accumulating from treatment of haematological malignancies 
that higher doses of HSC can promote faster platelet engraftment and are associated 
with better overall survival91,92,93. Consequently, a dose of 5 × 106 CD34+ cells/kg is 
currently defined as optimal94,95. 
 
[H3] Serotherapy 
Use of serotherapy, such as antilymphocyte or ATG, administered with or 
immediately following the conditioning regimen complements the 
immunosuppressive effect of conditioning, as the resulting T cell depletion can be 
critical in preventing the engraftment of any T cells that are reinfused; this effect is 
expected to be especially important with an unselected HSC graft. In addition, ATG 
has known immunomodulatory effects, including induction of adaptive regulatory 
T cells96, that might influence the earliest, and perhaps most critical, stages of 
immune reconstitution. 
 
[H3] Antimicrobial prophylaxis and monitoring 
General guidelines for prevention and management of infections in patients 
undergoing haematopoietic stem cell transplantation are available. Additionally in 
patients with MS, monitoring of cytomegalovirus and Epstein–Barr virus viraemia in 
the 3 months after transplantation is recommended, and might require a pre-emptive 
treatment in case of increasing viral load.”  
This recommendation is mostly based on the experience in allogeneic transplantation 
which results in a higher degree of post-transplantation immunosuppression than the 
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autologous; however, the administration of ATG in the latter, commonly done in 
protocols for treatment of patients with MS, can increase the risk of viral reactivation. 
 
 
 
[H1] Conclusions 
AHSCT provides a unique approach to the treatment of MS. Unlike current disease-
modifying therapies that either modulate or partially suppress the immune system, 
AHSCT relies on ablation of the immune and, to a variable extent, myeloid systems, 
followed by reconstitution of a profoundly modified immune system, in a process with 
characteristics of immune ‘resetting’. This approach is associated with risks that are 
generally greater than those associated with disease-modifying therapies, but are 
predominantly ‘front loaded’, whereas the risks of chronic or cyclic immune 
modulation or suppression, although initially low, increase over time. Furthermore, 
evidence from trials suggests that AHSCT is considerably more effective than current 
disease-modifying therapies at arresting inflammatory activity in MS. 
Patients who are most likely to benefit from AHSCT are those with RRMS, a high 
frequency of relapses, MRI markers of inflammatory activity, a young age and short 
duration of disease and limited disability, and who have been referred soon after a 
highly active MS therapy has failed and who are not affected by substantial 
comorbidities and cognitive impairment. As is the case for disease-modifying 
therapies, beneficial effects of AHSCT on neurological progression in MS are 
plausible, but cannot be reliably demonstrated without well-conducted, long-term 
randomized controlled trials. 
To date, a lack of support from the pharmaceutical industry, among other factors 
(Box 3), has slowed the development of AHSCT. Yet the current evidence from 
studies of AHSCT in MS makes a strong case to support the need for clinical trials, 
firstly to establish the safety, efficacy and cost-effectiveness of AHSCT in 
comparison with disease-modifying therapies in patients with highly active RRMS, 
and secondly to assess whether AHSCT might have a place in the treatment of early-
stage forms of progressive MS with inflammatory activity. Indeed, preliminary 
evaluations suggest that the treatment could be cost-effective97 and offer savings to 
patients and/or health authorities when compared with the cost of current biologics. 
Trials are needed to establish whether AHSCT could be recommended for the 
treatment of patients with inflammatory activity who have not tried high-efficacy 
disease-modifying therapies, but we believe that enough evidence already exists to 
support the use of AHSCT for treatment of patients with aggressive RRMS and those 
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with active RRMS in whom high-potency approved disease-modifying therapy has 
failed because of a lack of efficacy. Indeed, in December 2016, the Swedish Board of 
Health and Welfare included AHSCT as an option alongside fingolimod and 
alemtuzumab (as well as natalizumab for people with a negative JC virus antibody 
test or with low antibody levels) in their treatment recommendations for active 
RRMS98. We advocate healthcare organizations in all other countries to consider 
introducing AHSCT as the standard of care for these indications, and to regularly 
reassess and update their guidelines on the basis of new evidence that could alter 
the indications. 
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Box A | Subtypes of MS with unmet clinical needs 
Aggressive MS 
Aggressive MS represents almost 10% of all MS cases84. Definitions are variable, but 
commonly include frequent relapses, early acquisition of disability (often with 
incomplete resolution) and highly active disease seen as new Gadolinium-enhancing 
lesions and/or new T2 lesions on MRI84. ‘Rapidly evolving severe MS’ and ‘malignant 
MS’ are other terms used to refer to disease associated with a poor prognosis. We 
prefer the term ‘aggressive MS’ over ‘malignant MS’99 because it evokes a clinical 
challenge that can be tackled with aggressive therapies, including AHSCT. ‘Rapidly 
evolving severe MS’ was introduced by healthcare authorities, and is defined as 
relapsing–remitting MS with two or more disabling relapses in the past year, and one 
or more Gadolinium-enhancing lesion on MRI or an increase in the T2 lesion load 
from the previous MRI100. Although this term has a specific definition, external 
validation of the criteria is lacking, and we prefer the more generic term of aggressive 
MS. 
 
Treatment-refractory MS 
MS that persists or breaks through despite disease-modifying treatment is referred to 
as treatment-refractory MS. Currently, this definition implies failure to respond to a 
highly active therapy, though it has been used to refer to failure of first-line therapies. 
 
Progressive MS 
In aggressive and treatment-refractory MS, the eventual outcome is accumulation of 
disability, usually measured as persistent increases in Expanded Disability Status 
Scale (EDSS) scores in trials and, to a variable extent, in clinical practice. Increasing 
EDSS scores can result from residual damage from relapses or from progressive 
disease. Progressive disease, defined by gradual worsening of neurological function 
for at least 6 months with or without superimposed relapses, is associated with 
neurodegenerative processes that cause axonal loss. However, progression might 
be driven by inflammation behind the blood–brain barrier101-103, so targeting this 
inflammation might ameliorate progression to some extent, as suggested in trials of 
B-cell targeted therapies76. 
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Box 1 | Profile of a candidate for AHSCT 
 
• Relapsing–remitting MS or progressive MS for a short period of time 
• Recent clinical inflammatory activity (relapses) 
• Recent MRI inflammatory activity (Gadolinium-enhancing areas or an 
increase in the number of T2 lesions compared with a recent previous 
scan) 
• Young age (<45 years) 
• Short disease duration (no longer than 10 years) 
• Low to moderate disability (EDSS score lower than 6 or up to 6.5 if the 
highest score has been reached within the last few months and the 
patient has clinical and MRI inflammatory activity 
• Failure of approved, high-efficacy disease-modifying therapy 
(preferably not more than two disease-modifying therapies) 
• No substantial comorbidities 
• Has the capacity to give informed consent and to adhere to treatments 
and recommendations for prophylaxis in the immune compromised 
phases 
 
 
Box 2 | Recommended AHSCT methodology for treatment of MS 
 
 
Mobilization 
Cyclophosphamide at 2–4 g/m2 body surface area with mesna and 
hyperhydration, followed by 5–10 μg/kg G-CSF daily 
 
Immunoablative conditioning 
BEAM (bis-chloroethylnitrosourea (BCNU), etoposide, cytosine arabinoside 
(Ara-C and melphalan) 
 
Autograft 
Unselected peripheral blood product: minimum dose of 2 × 106 CD34+ cells/kg, 
and preferably ≥5 × 106 CD34+ cells/kg (before cryopreservation) 
 
Serotherapy for in vivo T cell-depletion 
Antithymocyte globulin (ATG) from horse or rabbit, alongside administration of 
corticosteroids to attenuate side-effects 
 
 
 
Box 3 | Challenges preventing randomized controlled trials of AHSCT for 
MS 
 
Lack of funding  
• AHSCT does not rely on proprietary new therapeutics and has not 
benefited from pharmaceutical industry support 
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• Competition for time, patients and resources with trials that are well 
supported by the pharmaceutical industry 
• Ever-increasing regulatory and administrative burden, which make low-
funded academic trials particularly unsustainable 
Clinician-related factors 
• Safety concerns were strongly established by early data on transplant-
related mortality (5–10%) and not updated to current figures (0.3%) 
• Competing interests related to personal financial support from the 
pharmaceutical industry that reduce incentive to develop AHSCT 
• A perception that AHSCT is not an elegant or ‘clever’ selective immune 
intervention 
• Unwillingness to collaborate with or rely on other specialists for the 
administration of treatment for MS 
Patient-related factors 
• Low acceptance of randomization to control therapies from patients 
who are entering a trial and want AHSCT 
Study design difficulties 
• Impossible double (patient) blinding 
• Continuous introduction of new and increasingly effective therapies for 
MS over past 15 years  
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Table 1 | Conditioning regimens for AHSCT reported to the European Society 
for Blood and Marrow Transplantation Registry (March 2016) 
 
Conditioning regimen Number 
of 
patients 
% 
Cyclophosphamide + thiotepa  3 0.4 
Busulphan + antithymocyte 
globulin  
11 1.5 
BEAM ± antithymocyte globulin  441 58.9 
Cyclophosphamide + 
antithymocyte globulin  
171 22.8 
Other  52 6.9 
No information on conditioning 
regimen 
71 9.5 
Total 749 100 
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Table 2 | Characteristics of patients treated with AHSCT in recent clinical 
papers that reported sufficient information about most variables we 
considered. 
Study 
Median 
age 
(years) 
Median EDSS 
score at 
baseline 
(range) 
Patients 
with 
RRMS 
(%) 
Median 
MS 
duration 
(years) 
Mean relapse 
rate in 
previous year 
Median 
number of 
previous 
treatments 
Reference 
Burman et al., 2014  31.0  6.0 (1.0-8.5) 85 6.3 4.1 2 10 
Burt et al., 2015 37.0  4.0 (3.0- 5.5) 81 5.1 >1.5 3 11 
Mancardi et al., 2015 36.0  6.5 (5.5- 6.5) 22 10.5 1.3 2 12 
Currò et al., 2015 28.0  6.0 (5.0- 7.0) 100 6.5 2.4 Not reported 
55 
Muraro et al., 2017 37.0  6.5 (1.5- 9.0) 22 6.8 Not reported 
2 61 
Shevchenko et al., 
2015 34.6  3.5 (1.5- 8.5) 46 
5.0 Not 
reported 
Not 
reported 
72 
Atkins et al., 2016 34 5.0 (3.0-6.0) 50 6.5 1.2 2 13 
Nash et al., 2017 37  4.5 (3.0- 5.5) 100 5.0 - 3 14 
 
Table 3 | Study design and outcomes in recent clinical studies of AHSCT for 
MS that reported sufficient information about most variables we considered. 
Study Sample size 
Median 
follow-up 
(months) 
Regimen type 
Patients with 
disability 
progression 
at 2 years (%) 
Patients with 
disability 
progression 
at 5 years (%) 
Reference 
Burman et al., 2014  41 47.4  Intermediate 10 23 10 
Burt et al., 2015 145 24.0 Low 7 13 11 
Mancardi et al., 2015 9 48.0 Intermediate 33 Not reported 
12 
Currò et al., 2015 7 60.0 Low 14 43 55 
Muraro et al., 2017 281 79.2  Mixed 16 54 61 
Shevchenko et al., 
2015 99 48.9 Intermediate 
1 13 72 
Atkins et al., 2016 24 80.4 Intermediate 30 30 13 
Nash et al., 2017 25 62  Intermediate 10 14 14 
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Figure legends 
Figure 1 | Outline of the autologous haematopoietic stem cell transplantation 
(AHSCT) procedure. Key steps of the procedure, drugs administered and white 
blood cell (WBC) and CD34+ haematopoietic stem cell (HSC) counts are arranged 
from top to bottom. The indicative time scale covers 10 weeks. The procedure starts 
with mobilization of HSCs from the bone marrow by injection of cyclophosphamide 
intravenously and granulocyte-colony stimulating factor (G-CSF) subcutaneously. 
The autologous graft harvested from the peripheral blood by leukoapheresis, and 
which can undergo CD34 selection to enrich HSCs or can be unmanipulated, is 
cryopreserved for subsequent use. The procedure can be paused for a few weeks or 
aborted, if necessary, at this point. Ablation of the immune and, to a variable extent, 
myeloid system is most commonly achieved by high-dose conditioning with a 
combination of cytotoxic drugs. The autologous haematopoietic graft is then 
reinfused (transplantation), and antithymocyte globulin is often administered with the 
conditioning regimen to deplete T cells, and owing to its long half-life it will also 
deplete and prevent the engraftment of any T cells that were present in the 
autologous graft (so called in vivo graft T cell depletion). Different levels of supportive 
care are required during the procedure; the conditioning, transplantation and in vivo 
T cell depletion steps require inpatient admission until the patient has recovered from 
neutropaenia and the management of any complications is complete. 
 
[Au: Edited to incorporate text from the figure that has been removed to 
simplify the figure. OK?] Figure 2. Proposed model of therapeutic mechanisms 
of autologous haematopoietic stem cell transplantation (AHSCT). Ablative 
conditioning leads to radical depletion of pathogenic immune cells. During the 
6 months after transplantation, homeostatic expansion of the T cell repertoire 
produces CD8+ and, in smaller numbers, CD4+ T cells, and antigens are encountered 
through infection and reimmunization. These processes are associated with 
potentiation of immune regulation. Subsequently, more effective 1–2 years after 
transplantation, immune renewal via thymopoiesis leads to increased numbers of 
naive CD4+ and CD8+ T cells and of CD31+ and sjTREC+ recent thymic emigrants, 
which results in diversification and normalization of the T cell repertoire. ,  In parallel 
naïve B cell reconstitution possibly restores the B cell repertoire and antibody 
diversity. Some normalization of gene expression profiles that favour restoration of 
tolerance has been demonstrated after completion of immune reconstitution at 
2 years after AHSCT. Further work is required to demonstrate which immune 
changes are essential for the efficacy of AHSCT in suppressing the inflammatory 
disease activity in multiple sclerosis. MAIT, mucosal associated invariant T cell; 
sjTREC, signal joint T- cell receptor excision circle. 
 
Figure 3 | Proportion of patients for whom no evidence of disease activity (NEDA) 
was achieved at 2 years with disease-modifying therapies (approved or 
effective in phase III trials) and AHSCT. Bars represent 95% confidence intervals. 
Although studies included different patient populations and smaller numbers in the 
AHSCT studies, higher rates of NEDA were achieved with AHSCT than with any 
other disease-modifying therapy, including those that are considered to have high 
efficacy. The findings suggest that AHSCT has a more profound effect on disease 
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activity than do current disease-modifying therapies. AHSCT, ablative therapy 
followed by autologous haematopoietic stem cell transplantation; NEDA, no evidence 
of disease activity. 
Figure 4 | Number of autologous haematopoietic stem cell transplantation 
(AHSCT) procedures for treatment of MS reported to the EBMT Registry and 
treatment-related mortality. The overall (1995–2016) treatment-related mortality is 
2.0%. Treatment-related mortality has decreased over time, however, and was 0.2% 
during the last five years (2012–2016). Data from 2016 (*), however are incomplete 
and data from 2017 are not yet available. 
 
Figure 5 | Estimated lymphoablative and myeloablative effects of autologous 
haematopoietic stem cell transplantation protocols for MS. The expected 
relative lymphoablative and myeloablative effects are depicted. Quantitative metrics 
are unavailable and the large size of circles indicate the error range in the estimation 
as well as the variability of the lympho- and myelo-ablative effects that are attained in 
the individual patient. The dotted line represents the threshold of the myeloablative 
effect above which haematopoietic stem cell (HSC) support is required for 
haematopoietic recovery and patient survival; in the most patients treated with 
protocols below this threshold haematopoiesis can recover without HSC 
transplantation, albeit with a longer recovery interval. These protocols are therefore 
considered non-myeloablative62. 
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Glossary 
 
Leukapheresis = a process that separates white blood cells from the peripheral blood, 
which in this article’s context is carried out with a semi-automated medical device to harvest 
the patient’s autologous haematopoietic stem cell-enriched blood product after mobilisation 
 
Bone marrow aplasia = a state of failure of the bone marrow to generate adequate 
numbers of haematopoietic stem cells to repopulate the blood with red blood cells, white 
blood cells and platelets, which in this article’s context follows the conditioning regimen 
(irreversibly after myeloablative conditioning, which requires haematopoietic stem cell 
support for survival) 
 
T cell receptor excision circles =  episomal DNA circles that are byproducts of intra-thymic 
T cell receptor rearrangement that persist in T cells as detectable markers of their recent 
thymic origin 
 
Recent thymic emigrants = T cells which have recently emerged from the thymus after 
differentiation and thymic selection 
 
Antithymocyte globulin (ATG): a T cell-depleting polyclonal immunoglobulin from horse or 
rabbit 
 
Uhtoff phenomenon = recurrence or worsening of pre-existing neurological symptoms, 
usually transient, experienced by patients with MS after exposure to internal (fever) or 
external (heat) high temperatures 
  
Pattern II MS pathology = one of four described patterns of tissue pathology in MS, 
characterized by anti-myelin antibodies and complement factors {Lucchinetti, 1996 #679} 
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